Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for PT Kimia Farma Tbk's 9-Day RSI or its related term are showing as below:
ISX:KAEF's 9-Day RSI is ranked worse than 51.61% of 124
companies
in the Medical Distribution industry
Industry Median: 53.43
vs ISX:KAEF: 53.67
PT Kimia Farma Tbk (ISX:KAEF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PT Kimia Farma Tbk 9-Day RSI Related Terms
ISX:KAEF vs MCK, CAH, COR: 9-Day RSI Comparison
For the Medical Distribution subindustry, PT Kimia Farma Tbk's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Tbk 9-Day RSI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Tbk's 9-Day RSI falls into.
PT Kimia Farma Tbk (ISX:KAEF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Tbk (ISX:KAEF) has a 9-Day RSI of 53.67 as of Jul. 19, 2026. According to the industry distribution chart, PT Kimia Farma Tbk ranks #64 out of 124 companies in the Medical Distribution industry, placing it in the top 51.6%.
Is PT Kimia Farma Tbk's 9-Day RSI too high?
PT Kimia Farma Tbk's current 9-Day RSI is 53.67. The Medical Distribution industry median 9-Day RSI is 53.43. PT Kimia Farma Tbk's value of 53.67 is 0.4% above this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #64 out of 124 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, PT Kimia Farma Tbk has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's 9-Day RSI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #64 out of 124 companies for 9-Day RSI. This places PT Kimia Farma Tbk in the lower half of its industry. The industry median 9-Day RSI is 53.43. PT Kimia Farma Tbk's value of 53.67 is 0.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Distribution company?
The median 9-Day RSI among Medical Distribution companies is 53.43, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current 9-Day RSI of 53.67 is 0.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median 9-Day RSI is 53.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current 9-Day RSI is 53.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.31, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current 9-Day RSI is 53.67 and 0.4% above the Medical Distribution industry median of 53.43. PT Kimia Farma Tbk's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current 9-Day RSI is 53.67 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued.
The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.31.
GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
9-Day RSI: 53.67
GF Value™: Rp581.31 vs. price of Rp456.00 (21.6% below fair value)
Industry Position: 0.4% above the Medical Distribution median (#64 of 124)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
58GF Score
Get the complete analysis for ISX:KAEF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
